Literature DB >> 17257454

Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed.

Aura Erazo Valle1, Tami Wisniewski, Jasmin Isabel Figueroa Vadillo, Thomas A Burke, Roberto Martinez Corona.   

Abstract

OBJECTIVE: An understanding of the incidence of chemotherapy-induced nausea and vomiting (CINV) may assist healthcare providers (HCP) when making treatment decisions. We investigated the incidence of CINV after highly or moderately emetogenic chemotherapy (HEC or MEC), in comparison with predictions of CINV by HCP. RESEARCH DESIGN AND METHODS: This prospective study was conducted at nine oncology centers in Mexico. Eligible patients were >/=18 years old and scheduled to receive a single, initial cycle of chemotherapy. Patients recorded nausea severity, episodes of emesis, and rescue medication use for the first 5 days after chemotherapy. HCP predicted the general incidence of acute (day 1) and delayed (days 2-5) CINV.
RESULTS: A total of 82 patients were enrolled, with complete data available for 73. Mean age was 50 years; 67 (92%) were women; and 57 (78%) received HEC, while 16 (22%) received MEC. HCP predictions were comparable to the incidence of acute CINV after HEC and MEC and of delayed CINV after MEC. However, HCP predictions underestimated delayed CINV after HEC. 75.4% of patients (95% CI: 62.2-85.9) reported delayed nausea and HCP predicted 41.7% (95% CI: 30.2-55.0); 63.2% of patients (95% CI: 49.3-75.6) reported delayed emesis and HCP predicted 31.8% (95% CI: 21.0-44.5). Limitations of the study include the small sample size, possible selection bias and lack of a standardized antiemetic regimen.
CONCLUSIONS: Healthcare providers underestimated the incidence of delayed CINV after HEC. There is a need for a better understanding of the incidence of delayed nausea and emesis, which remain common side-effects of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17257454     DOI: 10.1185/030079906X154033

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

1.  Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms.

Authors:  Sun Young Rha; Su Kyung Song; Chung Eun Lee; Yeonhee Park; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-06-08       Impact factor: 3.603

2.  Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.

Authors:  Ruey Kuen Hsieh; Alexandre Chan; Hoon-Kyo Kim; Shiying Yu; Jong Gwang Kim; Myung-Ah Lee; Johan Dalén; Hun Jung; Yan Ping Liu; Thomas A Burke; Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2014-08-14       Impact factor: 3.603

3.  Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists.

Authors:  Margarita Majem; Ma Estela Moreno; Núria Calvo; Anna Feliu; Javier Pérez; Ma Antonia Mangues; Agustí Barnadas
Journal:  Support Care Cancer       Date:  2010-11-18       Impact factor: 3.603

4.  Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Authors:  Steven M Grunberg; Matthew Dugan; Hyman Muss; Marie Wood; Susan Burdette-Radoux; Tracey Weisberg; Marisa Siebel
Journal:  Support Care Cancer       Date:  2008-11-27       Impact factor: 3.603

5.  Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting.

Authors:  Jing-Yu Tan; Lorna K P Suen; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-04-02       Impact factor: 3.603

6.  Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists.

Authors:  Asuka Ishikawa; Gen Ohara; Kensuke Nakazawa; Tomohiro Tamura; Shinya Sato; Katsunori Kagohashi; Koichi Kurishima; Yoko Ito; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2012-10-02

7.  Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.

Authors:  Cheryl Vidall; Paz Fernández-Ortega; Diego Cortinovis; Patrick Jahn; Bharat Amlani; Florian Scotté
Journal:  Support Care Cancer       Date:  2015-05-08       Impact factor: 3.603

8.  Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting.

Authors:  Kevin Yi-Lwern Yap; Xiu Hui Low; Alexandre Chan
Journal:  Toxicol Res       Date:  2012-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.